不可切除III期黑色素瘤新辅助靶向治疗期间18F-FDG PET/CT:早期代谢影像能否预测组织病理学缓解或复发
研究纳入20例BRAF突变不可切除III期黑色素瘤患者,在新辅助BRAF/MEK抑制剂治疗前及治疗2周、8周行18F-FDG PET/CT,术后5年内随访复查PET/CT。18例可评估病理缓解者中9例(50%)达病理完全或近完全缓解,EORTC或PERCIST缓解评估及SUVmax、SUVpeak、MATV、TLG均与病理结果不对应。17例R0切除者中8例复发,6例仅影像检出,其中4例为术后6个月内PET/CT检出;术前PET参数未预测复发。
要点
- 基线18F-FDG PET或PET缓解评估似乎不能预测新辅助BRAF/MEK抑制剂后的病理缓解。
- SUVmax、SUVpeak、MATV、TLG各时间点及3个初始时间点间变化在病理缓解组间无差异。
- PET/CT似乎有助于R0切除后早期检出复发,17例中8例复发、6例仅影像检出。
核心结论
- 基线18F-FDG PET或PET缓解评估在既往不可切除III期黑色素瘤患者中似乎不能预测新辅助BRAF/MEK抑制剂治疗后的病理缓解。
- PET/CT似乎有助于R0切除后早期检出复发。
研究设计与样本
- 研究纳入20例BRAF突变、不可切除III期黑色素瘤患者,术前接受BRAF/MEK抑制剂治疗。
- 基线及治疗开始后2周、8周行18F-FDG PET/CT,切除术后5年随访特定时间点行PET/CT。
- 病理缓解在清扫标本上评估,缓解监测采用SUVmax、SUVpeak、MATV、TLG及EORTC和PERCIST标准。
主要发现
- 18例可评估病理缓解,9例(50%)达病理完全或近完全缓解,9例(50%)为病理部分或无缓解。
- EORTC或PERCIST缓解测量与病理结果不对应。
- SUVmax、SUVpeak、MATV、TLG在所有时间点及3个初始时间点间的绝对或百分比变化在组间无差异。
- 随访中17例R0切除患者中8例复发,6例仅影像检出,其中4例为术后6个月内PET/CT检出。
- 术前PET参数未预测复发。
关键数值与推荐
- 病理缓解评估:18例中9例(50%)病理完全或近完全缓解,9例(50%)病理部分或无缓解。
- 缓解监测标准:EORTC和PERCIST标准,测量指标为SUVmax、SUVpeak、MATV、TLG。
- 复发检出:17例R0切除患者中8例复发,6例仅影像检出,4例为术后6个月内PET/CT检出。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to investigate whether 18F-FDG PET/CT can predict histopathological response or recurrence in BRAF-mutated unresectable locally advanced stage III melanoma treated with neoadjuvant BRAF/MEK inhibition followed by resection and the value of PET in detecting early recurrence after resection. PATIENTS AND METHODS: Twenty BRAF-mutated, unresectable stage III melanoma patients received BRAF/MEK inhibitors before surgery. 18F-FDG PET/CT was performed at baseline and 2 and 8 weeks after initiation of therapy. After resection, PET/CT was performed at specific time points during 5 years of follow-up. Pathological response was assessed on the dissection specimen. Response monitoring was measured with SUVmax, SUVpeak, MATV, and TLG and according to EORTC and PERCIST criteria. RESULTS: Pathological response was assessed in 18 patients. Nine patients (50%) had a pathologic complete or near-complete response, and 9 (50%) had a pathologic partial or no response. EORTC or PERCIST response measurements did not correspond with pathologic outcome. SUVmax, SUVpeak, MATV, and TLG at all time points and absolute or percentage change among the 3 initial time points did not differ between the groups.During follow-up, 8 of 17 patients with R0 resection developed a recurrence, 6 recurrences were detected with imaging only, 4 of which with PET/CT in less than 6 months after surgery. PET parameters before surgery did not predict recurrence. CONCLUSIONS: Baseline 18F-FDG PET or PET response in previous unresectable stage III melanoma patients seems not useful to predict pathologic response after neoadjuvant BRAF/MEK inhibitors treatment. However, PET/CT seems valuable in detecting recurrence early after R0 resection.
引用
- van der Hiel B, Blankenstein SA, Aalbersberg EA, et al. 18F-FDG PET/CT During Neoadjuvant Targeted Therapy in Prior Unresectable Stage III Melanoma Patients: Can (Early) Metabolic Imaging Predict Histopathologic Response or Recurrence? Clin Nucl Med. 2022. PMID: 35452004. doi:10.1097/RLU.0000000000004217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。